iwAL 2018 Session V

 

Is MRD Already a Surrogate for Survival?

In this stimulating session, Andriano Venditti, MD, Roland Walter, MD, PhD, and Farhad Ravandi, MD, present talks on the hot topic of utilizing MRD in clinical practice. E-learning webcasts include MRD as a therapy-dependent prognostic factor, treatment algorithms and whether MRD is indeed a surrogate for survival.

Presentations
MRD as a Therapy-Dependent Prognostic Factor
Adriano Venditti, MD
University of Rome Tor Vergata, Rome, Italy
10 February, 2018

Adriano Venditti, MD, from the University of Rome Tor Vergata, Rome, Italy, discusses the potential of MRD as a therapy-dependent prognostic factor.

MRD-Based Treatment Algorithms
Roland Walter, MD, PhD
Fred Hutchinson Cancer Research Center, Seattle, WA
10 February, 2018

Roland Walter, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA, gives a presentation on treatment algorithms based on MRD testing.

Is MRD Already a Surrogate for Survival?
Farhad Ravandi, MD
University of Texas MD Anderson Cancer Center, Houston, TX
10 February, 2018

In his talk, Farhad Ravandi, MD, University of Texas MD Anderson Cancer Center, Houston, TX, explores a key question: is MRD already a surrogate for survival?